ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Cemiplimab combined with chemotherapy versus chemotherapy in advanced non-small cell lung cancer: an updated EMPOWER-Lung 3 trial-based cost-effectiveness analysis

Zhu, Gaofeng; Cai, Hongfu; Zheng, Zhiwei*广东省人民医院; 南方医科大学; 汕头大学
Therapeutic Advances in Medical Oncology2023DOI: 10.1177/17588359231213619
4阅读
引用收藏
分享

摘要

Objective: Cemiplimab combined with chemotherapy has emerged as a promising treatment option for advanced non-small cell lung cancer (NSCLC). Accordingly, this study has been conducted to evaluate the cost-effectiveness of this combination therapy in comparison to chemotherapy alone from the perspective of the United States healthcare system.Methods: The present study is based on a partitioned survival model developed from clinical data obtained during the 2-year follow-up of the phase III EMPOWER-Lung 3 part 2 trial. The purpose of this investigation is to estimate the 10-year life expectancy and total healthcare costs of patients with advanced NSCLC by leveraging primary outcomes that evaluated costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratio (ICER).To establish the willingness-to-pay (WTP) threshold for the analysis, a value of $150,000/QALY was adopted. Sensitivity analysis was performed to determine the impact of varying levels of uncertainty on the results of this study.Results: When compared to chemotherapy alone, the addition of cemiplimab to chemotherapy has been demonstrated to result in an incremental gain of 1.593 QALY at an additional cost of $109351.298. This equates to an incremental cost-effectiveness ratio (ICER) of $68644.883/QALY. One-way sensitivity analyses were conducted on the model, which acknowledged the influence of several parameters, such as subsequent costs, the utility of progressive disease, the cost of best supportive care, the cost of cemiplimab per mg, and the utility of progression-free survival on the outcomes. Nonetheless, none of these parameters yielded an ICER lower than the WTP threshold.Conclusions: From the perspective of the United States healthcare system, the utilization of cemiplimab in combination with chemotherapy as a first-line treatment option for NSCLC appears to be a cost-effective approach as compared to using chemotherapy as a standalone therapy.

学科与关键词

关键词
cemiplimabchemotherapycost-effectiveness analysisnon-small cell lung cancerpartitioned survival model
相关
加载中…
  • A cost-effectiveness analysis of first-line toripalimab plus chemotherapy in advanced nonsquamous non-small cell lung cancer in China
    Zheng, Zhiwei; Zhu, Gaofeng; Cao, Xueqiong; Cai, Hongfu*; Zhu, Huide*Expert Review of Clinical Pharmacology, 2023, 16(3): 267-273.被引 2
  • Cost-effectiveness analysis of pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer
    Liu, Tong; Liu, Shuang; Guan, Shangwei; Tai, Yu; Jin, Yao; Dong, Mei*JOURNAL OF CHEMOTHERAPY, 2023, 35(8): 745-752.被引 4
  • Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non-Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01)
    Wang, Zhijie; Wu, Lin; Li, Baolan; Cheng, Ying; Li, Xiaoling; Wang, Xicheng; Han, Liang; Wu, Xiaohong; Fan, Yun; Yu, Yan; Lv, Dongqing; Shi, Jianhua; Huang, Jianjin; Zhou, Shaozhang; Han, Baohui; Sun, Guogui; Guo, Qisen; Ji, Youxin; Zhu, Xiaoli; Hu, Sheng; Zhang, Wei; Wang, Qiming; Jia, Yuming; Wang, Ziping; Song, Yong; Wu, Jingxun; Shi, Meiqi; Li, Xingya; Han, Zhigang; Liu, Yunpeng; Yu, Zhuang; Liu, An-Wen; Wang, Xiuwen; Zhou, Caicun; Zhong, Diansheng; Miao, Liyun; Zhang, Zhihong; Zhao, HuiJournal of Clinical Oncology, 2023, 41(3): 651-+.被引 36
查看全部 →

发表信息

论文状态
公开发表
期刊
Therapeutic Advances in Medical Oncology
发表日期
2023
卷期
第 15 卷
页码
17588359231213619
DOI
10.1177/17588359231213619
语言
ENGLISH
成果收录
SCIE

作者

  • Z

    Zhu, Gaofeng (第一作者)

    guangdong prov peoples hosp · southern med univ

  • C

    Cai, Hongfu

    fujian med univ

查看全部 3 位作者收起作者
  • Z

    Zheng, Zhiwei (通讯)

    shantou univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417